DEF: Theriva Biologics Seeks Shareholder Approval for Warrant Issuance

Theriva Biologics, Inc. is holding a Special Meeting to approve the issuance of up to 16.18 million common shares from new warrant exercises, a condition for potential capital.

Summary

• A Special Meeting of Stockholders will be held on December 15, 2025, to vote on two proposals.
• The primary proposal is to approve the issuance of up to 16,184,560 shares of common stock upon the exercise of new common stock purchase warrants.
• These new warrants were issued to institutional investors in a private placement offering that closed on October 17, 2025.
• The new warrants were issued as an inducement for investors to immediately exercise existing warrants (from September 2024 and May 2025 private placements) for cash at a reduced exercise price of $0.54 per share.
• The issuance of these 16,184,560 shares requires stockholder approval under NYSE American Company Guide Section 713(a) because the exercise price ($0.54) is below the market price ($0.84 on Oct 15, 2025) and the number of shares exceeds 20% of outstanding common stock.
• If approved, the company could receive up to approximately $8.7 million in gross proceeds from the exercise of these new warrants.
• The second proposal is to approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies for the Warrant Exercise Proposal.
• As of October 30, 2025, there were 33,739,643 shares of common stock outstanding.
• The Board of Directors unanimously recommends voting FOR both proposals.

Sentiment

Score: 6

Explanation: The filing is a procedural proxy statement for a capital raise. While the potential for $8.7 million in proceeds is positive for funding operations, the associated dilution and the need for stockholder approval for a transaction already consummated (the inducement) introduce elements of caution. The reduced exercise price for existing warrants and the issuance of new warrants as an inducement suggest a need for capital and a willingness to offer favorable terms to investors, which can be viewed neutrally to slightly negatively depending on the company's financial position and alternatives.

Positives

• Approval of the Warrant Exercise Proposal could enable the company to receive up to approximately $8.7 million in gross proceeds from the exercise of the new warrants, which would support operations.
• The inducement agreement successfully led to the immediate exercise of existing warrants, providing the company with cash proceeds.

Negatives

• Approval of the Warrant Exercise Proposal will result in future dilution for existing stockholders upon the issuance of 16,184,560 additional shares of common stock.
• The potential sale of these new shares into the public market could adversely affect the market price of the company's common stock.
• Failure to approve the Warrant Exercise Proposal would prevent the company from realizing the potential $8.7 million in gross proceeds and would incur substantial additional costs for holding more stockholder meetings.

Risks

• Future dilution of existing stockholders' ownership interests if the 16,184,560 new warrants are exercised.
• Potential adverse impact on the market price of common stock due to the sale of newly issued shares into the public market.
• Risk of not obtaining stockholder approval for the Warrant Exercise Proposal, leading to inability to realize potential proceeds and incurring additional meeting costs.
• The company is obligated to call meetings every 60 days until stockholder approval is obtained or the new warrants are no longer outstanding if approval is not secured at the first meeting.

Future Outlook

The company is seeking stockholder approval to enable the exercise of new warrants, which, if approved and fully exercised for cash, could provide approximately $8.7 million in gross proceeds to fund operations. The new warrants are exercisable commencing on the effective date of stockholder approval and expire on the fifth anniversary of that date. The company has committed to using reasonable best efforts to obtain stockholder approval and will hold subsequent meetings every 60 days if initial approval is not secured.

Management Comments

• Your vote is very important. Whether or not you plan to attend the Special Meeting, we encourage you to read the accompanying Proxy Statement and to submit your proxy or voting instructions as soon as possible.
• In order to ensure the representation of a quorum at the Special Meeting, stockholders who do not expect to attend the Special Meeting are urged to vote as soon as possible.
• The Board believes that if at the Special Meeting, the number of votes represented by shares of our Common Stock, present or represented and voting in favor of the Warrant Exercise Proposal, is insufficient to approve the Warrant Exercise Proposal or establish a quorum, it is in the best interests of the stockholders to enable the Board to continue to seek to obtain a sufficient number of additional votes to approve the Warrant Exercise Proposal.

Industry Context

This filing is a procedural step for Theriva Biologics to secure additional capital through warrant exercises, a common financing mechanism for biotechnology or development-stage companies. The need for stockholder approval due to NYSE American rules highlights the company's reliance on equity financing and the potential for dilution, a frequent characteristic in industries requiring significant R&D investment and facing long development cycles without immediate product revenues. The reduced exercise price for existing warrants and issuance of new warrants as an inducement reflects market conditions and the company's efforts to attract and retain investor interest in its capital structure.

Stakeholder Impact

• Shareholders: Will experience future dilution of their ownership interests if the new warrants are exercised. The market price of common stock could be adversely affected by the sale of new shares. However, the capital raised could support company operations, potentially benefiting long-term value.
• Institutional Investors (Warrant Holders): Benefit from the inducement agreement, allowing them to exercise existing warrants at a reduced price and receive new warrants, providing potential future upside.

Next Steps

• Hold a Special Meeting of Stockholders on December 15, 2025, to vote on the Warrant Exercise Proposal and the Adjournment Proposal.
• If the Warrant Exercise Proposal is not approved, the company is obligated to call subsequent stockholder meetings every 60 days until approval is obtained or the New Warrants are no longer outstanding.
• File a registration statement for the resale of the New Warrant Shares within 30 calendar days following the Inducement Agreement date (October 16, 2025) and use commercially reasonable efforts to have it declared effective by the SEC within 60-90 days.
• Keep the resale registration statement effective until no holder owns New Warrants or New Warrant Shares.

Key Dates

Recommendation

The filing outlines a necessary procedural step for Theriva Biologics to potentially secure significant capital through warrant exercises. While the potential $8.7 million in gross proceeds is crucial for funding operations, the substantial dilution (nearly 50% of current outstanding shares) upon full exercise of the new warrants presents a significant headwind for existing shareholders. The reduced exercise price for existing warrants and the issuance of new warrants as an inducement suggest a need for capital and a willingness to offer favorable terms to investors. Investors should 'hold' to observe the outcome of the stockholder vote and the subsequent impact on the company's capital structure and market valuation, weighing the benefits of increased funding against the costs of dilution.

Keywords

Theriva Biologics, TOVX, SEC Filing, Proxy Statement, Special Meeting, Warrants, Private Placement, Stockholder Approval, Dilution, Capital Raise, NYSE American, Common Stock, Corporate Governance